Four-Arm Randomized Phase II Study of SGI-110: 5 days, versus 10 days, versus 5 days + idarubicin, versus 5 days + cladribine, in Previously Untreated Patients >/= 70 Years with Acute Myeloid Leukemia
The goal of this clinical research study is to compare different treatment schedules using the drug SGI-110 alone or in combination with other drugs. Researchers want to learn more about how these different treatment schedules may help to control AML. The safety of these treatments will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 04/04/2014
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: